Has Lorrie McGill, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,467,437 in general payments to Lorrie McGill, MD across 804 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Lorrie McGill, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Lorrie McGill, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Lorrie McGill, MD

Family Medicine · Papillion, NENPI 1053300244

Payments from drug & device makers

$1,467,437in general payments, 2019–2025

Across 804 payments — averaging $1825.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Pfizer$437K
Takeda Pharmaceuticals U.S.A., Inc.$199K
GSK$155K
Amgen$137K
Kowa Research Institute, Inc.$124K
Valneva Austria GmbH$106K
plus $310K from 53 others

$126,603in research payments, 2019–2025

Across 3 payments — averaging $42,201 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Valneva Austria GmbH$126K
Eli Lilly$513

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Pfizer	77	$436,683
Takeda Pharmaceuticals U.S.A., Inc.	18	$199,337
GSK	42	$155,377
Amgen(2 entities)	45	$136,588
Kowa Research Institute, Inc.	61	$123,841
Valneva Austria GmbH	8	$105,865
Eli Lilly	10	$86,991
Sanofi US Services Inc.	20	$61,949
AbbVie(2 entities)	186	$57,697
AstraZeneca	29	$47,324
Emergent Biosolutions Inc.	1	$41,865
Novartis	4	$6,541
Bayer	11	$1,080
Lexicon Pharmaceuticals, Inc.	1	$1,011
Otsuka America Pharmaceutical, Inc.	44	$735
Eli Lilly Export S.A. Puerto Rico Branch	2	$622
Lilly USA, LLC	43	$611
Antares Pharma, Inc.	45	$452
Novo Nordisk	20	$337
Actelion Pharmaceuticals US, Inc.	5	$259
Amarin Pharma, Inc.	16	$253
Johnson & Johnson(2 entities)	11	$193
Supernus Pharmaceuticals, Inc.	3	$147
Merck	9	$132
Mayne Pharma Commercial LLC	11	$122
Astellas Pharma US Inc	5	$108
Sanofi-aventis U.S. LLC	5	$100
Lundbeck LLC	6	$97
Vanda Pharmaceuticals Inc.	5	$93
Axsome Therapeutics, Inc.	5	$83
Esperion Therapeutics, Inc.	5	$77
Biohaven Pharmaceuticals, Inc.	4	$63
Exact Sciences	3	$59
Biohaven Pharmaceutical Holding Company Ltd.	2	$53
Abbott	3	$53
Genentech USA, Inc.	3	$51
Seqirus USA Inc	2	$49
Jazz Pharmaceuticals Inc.	3	$48
Nestle Healthcare Nutrition Inc.	3	$45
Eisai Inc.	3	$43
Sanofi	2	$42
Coopersurgical, Inc.	2	$36
Ironwood Pharmaceuticals, Inc	2	$31
Arbor Pharmaceuticals, Inc.	2	$31
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	2	$27
Vertical Pharmaceuticals, LLC	2	$26
Sanofi Pasteur Inc.	1	$25
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	1	$21
Ultragenyx Pharmaceutical Inc.	1	$18
Acella Pharmaceuticals, LLC	1	$18
Grifols USA, LLC	1	$18
Sunovion Pharmaceuticals Inc.	1	$17
Kowa Pharmaceuticals America, Inc.	1	$14
Medline Industries LP	1	$14
Mylan Specialty L.p.	1	$14
Noven Therapeutics, LLC	1	$14
Philips North America LLC	1	$13
Boehringer Ingelheim	1	$12
E.r. Squibb & Sons, L.L.C.	1	$12

How this compares

$1,467,437 in reported general payments places this provider in the 95th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska →

Medicare billing

Part B allowed, 2024

$82,483

Medicare patients

131

Services billed

1,487

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family medicine in Papillion

Jeffry StrohmyerPapillion$9K
Sarah HurdPapillion$9K
Brandon EssinkCreighton$92.8M
Adam BroszGrand Island$60M
David EnszSouth Sioux City$33.3M
Allen HuntLincoln$17.2M
Thomas WolfFremont$8.2M
William FitzgibbonsElkhorn$7M
Kenneth BladOmaha$1.6M
Ralph HaukeOmaha$657K

See the full list for Nebraska →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →